ERBB2 and melanoma: Similar to these findings with ALK+ NSCLC cells, it is reported that in DTP cells in EGFR+ NSCLC, HER2+ breast cancer, and BRAF+ melanoma, the gene signatures of ROS production are increased after treatment with clinically relevant TKIs and the expression of antioxidant genes is also decreased [27].